Table 1.
Patients’ and tumors’ characteristics.
| Feature | Ν | % |
|---|---|---|
| Selected patients | 171/186 | 91.5 |
| Regimen | ||
| Carboplatin–paclitaxel | 157 | 91.8 |
| Other platinum-based treatment | 14 | 8.2 |
| Median age (range) years | 60 (28–84) | |
| ≤70 years | 145 | 84.8 |
| >70 years | 26 | 15.2 |
| Histology | ||
| Serous | 110 | 64.3 |
| Mucinous | 15 | 8.8 |
| Endometrioid | 19 | 11.1 |
| Clear cell | 7 | 4.1 |
| Other epithelial 1 | 20 | 11.7 |
| Grade | ||
| Well differentiated | 15 | 8.8 |
| Moderate | 64 | 37.4 |
| Poorly differentiated | 92 | 53.8 |
| Stage | ||
| I | 26 | 15.2 |
| II | 22 | 12.9 |
| III | 104 | 60.8 |
| IV | 19 | 11.1 |
| Surgery | ||
| Optimal | 48 | 28.1 |
| Others | 121 | 70.8 |
| Unknown | 2 | 1.2 |
| Second-look laparotomy (SLL) | ||
| PCR 2 | 12 | 7.0 |
| PPR Micro 3 | 15 | 8.8 |
| PPR Macrp 4 | 30 | 17.5 |
| Without SLL/unknown | 116 | 66.7 |
| Platinum-sensitivity | ||
| YES | 79 | 46.2 |
| NO | 37 | 21.6 |
| Unknown | 55 | 32.2 |
| Median survival (range) months | ||
| mPFS (95%CI) 5 | 11.4 (95%Cl 9.2–13.5) | |
| mOS (95%CI) 6 | 43.1 (95%Cl 34.9–51.4) |
1 Undifferentiated, unclassified, mixed, unknown; 2 pathological complete response; 3 microscopic partial response; 4 macroscopic partial response; 5 median progression-free survival; 6 median overall survival.